Pomerantz Roger
SEC-identified person · CIK 1614936 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Enlivex Ltd. ENLV | Director | filed 2026 - 2026 |
| Intec Parent Inc. NTEC | Director | filed 2021 - 2025 |
| Viracta Therapeutics, Inc. VIRX | Director | filed 2021 - 2024 |
| Contrafect Corp CRFX | Director · Chief Executive Officer | filed 2014 - 2022 |
| Intec Pharma Ltd. NTEC | Director | filed 2019 - 2020 |
| Seres Therapeutics, Inc. MCRB | Director · President and CEO | filed 2015 - 2019 |
| Rubius Therapeutics, Inc. RUBY | Director | filed 2018 - 2018 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.